ProCE Banner Activity

Updated Results From a Randomized Phase III Trial of Avatrombopag in Patients With Chronic ITP

Slideset Download
Conference Coverage
Avatrombopag increases cumulative platelet response rate vs placebo in refractory chronic ITP.

Released: December 11, 2019

Expiration: December 09, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company